ESMO | sciencenewsnet.in

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

September 30, 2019 sarah Jonas 0 Comments Colorectal Cancer, ESMO, MD Anderson Cancer Center, NEJM

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Research Results

Adding targeted therapy drug to hormone therapy helps women with aggressive breast cancer live longer

September 29, 2019 sarah Jonas 0 Comments Breast Cancer, Cancer, ESMO, European Society for Medical Oncology

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.

Research Results

PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients

September 28, 2019 sarah Jonas 0 Comments ESMO, MD Anderson Cancer Center, Ovarian Cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.